Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Turunen, Antti; Valtola, Jaakko; Partanen, Anu; Ropponen, Antti; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Ågren, L.; Penttilä, Karri; Keskinen, Leena; Savolainen, Eeva‐Riitta; Pyörälä, Marja; Kuittinen, Taru; Selander, Tuomas; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville

doi:10.1080/10428194.2020.1762879

Cited by 14 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings argue that the KIR mechanism of tumor targeting seen in the allogeneic stem cell transplantation might also apply in the APBHSCT. Recently, our group published a more detailed analysis of the autograft collected and infused immune effector cells affecting clinical outcomes post-APBHSCT [6] and our findings have recently confirmed [8][9][10]; thus, supporting the concept of autologous graft versus tumor effect [11]. This current study with a longer term follow-up supports our practice change to collect A-ALC ≥ 0.5 × 10 9 cells/kg in addition to CD34 to improve clinical outcomes for lymphoma patients undergoing APBHSCT.…”

Section: Discussionsupporting

confidence: 74%

Long‐term outcome of immunologic autograft engineering

Porrata

Inwards

Ansell

et al. 2022

eJHaem

View full text Add to dashboard Cite

Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still confers survival benefit with a longer follow‐up. With a median follow‐up of 127.6 months, patients infused with an A‐ALC ≥ 0.5 × 109 cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224–0.687, p < 0.001) and progression‐free survival (HR = 0.413, 95% CI: 0.253–0.677), p < 0.0004). This study supports that A‐ALC provides long‐term survival benefit post APBHSCT.

show abstract

Section: Discussionsupporting

confidence: 74%

Long‐term outcome of immunologic autograft engineering

Porrata

Inwards

Ansell

et al. 2022

eJHaem

View full text Add to dashboard Cite

show abstract

“…Altogether, 136 patients with NHL intended to proceed to auto‐SCT were mobilized with chemotherapy plus granulocyte colony‐stimulating factor (G‐CSF) and recruited at the time point of apheresis into the prospective noninterventional GOA study between May 2012 and December 2016 at the University Hospitals of Kuopio, Oulu, and Tampere 19 . Sixty‐eight patients (50%) of those with a diagnosis of diffuse large B‐cell lymphoma (DLBCL) were included in this study.…”

Section: Methodsmentioning

confidence: 99%

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto‐SCT). Study Design and Methods This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics and graft cellular content on hematologic recovery and outcome after auto‐SCT among 68 patients with DLBCL. Results Better mobilization capacity as manifested by blood CD34+ cell count >32 × 106/L and CD34+ cell yield of the first apheresis >2.75 × 106/kg correlated with faster neutrophil (P = .005 and P = .017) and platelet (P = .002 and P < .001) recovery. A higher number of infused CD34+ cells (> 2.65 × 106/kg) was associated with better 5‐year overall survival (OS; 95% vs 67%, P = .012). The graft CD34+CD133+CD38− cell count >0.07 × 106/kg was predictive of better 5‐year OS (87% vs 63%; P = .008) and higher graft CD3+ cell count (>23.1 × 106/kg) correlated also with better 5‐year OS (80% vs 40%, P = .008). In multivariate analysis only disease status of CR I at auto‐SCT was associated with better progression‐free survival (P = .014) and OS (P = .039). Conclusion The mobilization capacity of CD34+ cells impacted on early hematologic recovery in patients with DLBCL after auto‐SCT. Higher graft CD34+ cell count and both CD34+CD133+CD38− and CD3+ cells were also associated with better OS. The effect of optimal graft cellular composition on outcome in DLBCL should be evaluated in a randomized study.

show abstract

“…The lower yields of CD56+ cells did not impact the progression‐free survival or overall survival 17 . A similar analysis of graft composition in lymphoma patients showed higher numbers of CD3+/CD4+ cells in the graft to be positively progonostic for outcome in lymphoma patients 18 . In the patients with diffuse large B‐cell lymphoma, higher CD3+ count was also positively prognostic for a positive prognostic value regarding 5‐year‐overall‐survival 19 .…”

Section: Discussionmentioning

confidence: 84%

“…17 A similar analysis of graft composition in lymphoma patients showed higher numbers of CD3+/CD4+ cells in the graft to be positively progonostic for outcome in lymphoma patients. 18 In the patients with diffuse large B-cell lymphoma, higher CD3+ count was also positively prognostic for a positive prognostic value regarding 5-year-overall-survival. 19 The authors are not aware of data reporting the influence of CD3+ or CD56+ cell counts regarding the outcome of Ewing sarcoma.…”

Section: Discussionmentioning

confidence: 86%

Analysis of stem cell collections in adult patients with Ewing sarcoma

et al. 2022

View full text Add to dashboard Cite

Background: Ewing sarcoma is one of the most frequent soft-tissue tumors in pediatric patients. The current treatment protocols recommend stem cell apheresis (SCA) after completion of the second course of induction therapy with vincristine, ifosfamide, doxorubicine, and etoposide (VIDE). The feasibility of SCA and graft compositions in adult patients with Ewing sarcoma have not been previously analyzed. Methods and Materials:The authors analyzed 29 stem cell collections of 19 adult patients (9 male, 10 female) at a median age of 27 (range 19-53) years mobilized after VIDE (n = 17), cyclophosphamide/topotecan (n = 1) or vincristine, dactinomycin and ifosfamide (n = 1) chemotherapy. All patients were mobilized with filgrastim 5 μg/kg twice daily from day +7 of chemotherapy. The collections were performed if CD34+ cell count in peripheral blood was >10/μL. The target yields were ≥4Â10 6 CD34+ cells/kg body weight.Results: Median CD34+ cells/μL in peripheral blood before SCA were 45.8 (range 6.7-614.4)/μL. The median cumulative yields were 10.6 (range 1.5-38.8) CD34+ cells/kg body weight and ≥2Â10 6 in all but two patients (89%). CD34, CD3, and CD56 yields in collections after the third VIDE and after later courses did not differ. Four patients underwent high-dose therapy with autologous transplantation, and all were engrafted. Discussion: Stem cell mobilization is feasible in most Ewing sarcoma patients.Additionally, the present study's data suggest that it is safe to postpone stem cell collection to a later VIDE chemotherapy cycle if medically indicated. K E Y W O R D S apheresis, autologous stem cell transplantation, Ewing sarcoma, stem cell mobilization Georg-Nikolaus Franke and Roald Pfannes contributed equally and share first authorship.Madlen Jentzsch and Vladan Vucinic contributed equally and share senior authorship.

show abstract

Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Cited by 14 publications

References 34 publications

Long‐term outcome of immunologic autograft engineering

Long‐term outcome of immunologic autograft engineering

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Analysis of stem cell collections in adult patients with Ewing sarcoma

Contact Info

Product

Resources

About